Antibody Fragments Market to Grow with a CAGR of 4.90% through 2028
Rising incidence of chronic diseases and
increasing investments in biopharmaceuticals are factors driving the global Antibody
Fragments market in the forecast period 2024-2028
According to TechSci Research report, “Antibody
Fragments Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Antibody Fragments Market stood at USD 7.25 Billion
in 2022 and is anticipated to grow with a CAGR of 4.90% in the forecast period,
2024-2028. The global antibody fragments market has witnessed remarkable growth
in recent years, driven by a range of factors that reflect the increasing
importance of these therapeutic molecules in the field of healthcare and
biotechnology. Antibody fragments are smaller segments of full-sized
antibodies, offering advantages such as improved tissue penetration, reduced
immunogenicity, and enhanced manufacturing efficiency. One of the primary
drivers of the global antibody fragments market is the escalating prevalence of
chronic diseases such as cancer, autoimmune disorders, and cardiovascular
diseases. Antibody fragments have shown promising therapeutic potential in the
treatment of these conditions, leading to increased research and development
efforts in this area.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Antibody
Fragments Market”
Advancements in biotechnology have
played a pivotal role in driving the growth of the antibody fragments market.
Technological breakthroughs, such as improved screening techniques, cell-line
development, and protein engineering, have enabled the efficient production of
antibody fragments, making them more accessible for research and clinical
applications. The shift towards personalized medicine has significantly
increased the demand for targeted therapies. Antibody fragments can be
engineered to target specific antigens, making them a valuable asset in the
development of personalized treatment options. This growing demand for
precision medicine has propelled the adoption of antibody fragments in the
healthcare sector.
Orphan diseases, which affect a
relatively small percentage of the population, have gained attention in recent
years. The development of traditional drugs for these diseases may not be
economically viable, but antibody fragments offer a cost-effective solution due
to their adaptability and lower production costs. This has stimulated research
and investment in the development of antibody fragments for orphan diseases. The
biopharmaceutical industry has witnessed substantial investments from both
public and private sectors. Antibody fragments are a significant part of this
sector due to their potential in the development of novel biologics and
biosimilars. As a result, increased investments in biopharmaceuticals have
driven the growth of the antibody fragments market.
The Global Antibody Fragments Market is segmented into
product type, application, specificity and company
Based on Application, the Immunodeficiency segment has
emerged as the predominant market leader.
Antibody
fragments are being engineered to target specific immune components, allowing
for precise immunomodulation. In immunodeficiency disorders characterized by
overactive immune responses, such as certain autoimmune diseases, antibody
fragments can help control the immune system's hyperactivity, providing
therapeutic benefits. Ongoing research
and development efforts have led to the discovery of novel antibody fragments
with enhanced therapeutic potential. These innovations have opened up new
avenues for the treatment of immunodeficiency disorders, further fueling the
demand for antibody fragments.
Based on region, North America segment is expected to
grow during the forecast period. The United States, in particular,
has a regulatory environment that is conducive to biopharmaceutical innovation.
The FDA's expedited approval pathways for biologics have incentivized research
and development efforts in antibody fragments. North America has attracted substantial investments
and funding for biotechnology research and development. Venture capital firms
and government agencies have shown a keen interest in supporting projects
related to antibody fragments, providing the necessary financial resources for
advancements in the field.
The Asia Pacific region is experiencing rapid market
growth. Strong intellectual property protections in Asia Pacific have
encouraged companies and researchers to invest in antibody fragment technology
without the fear of intellectual property theft or infringement.
Major companies operating in Global Antibody
Fragments Market are:
- Genentech Inc.
- AbbVie Inc.
- Albynx, a Sanofi Company
- Johnson and Johnson
- Pfizer Inc.
- Bristol-Myers Squibb
- Eli Lilly and Company
- Novartis AG
Download
Free Sample Report
Customers can also request for 10%
free customization on this report
“The global antibody fragments market is on a robust
growth trajectory, driven by a confluence of factors that include advancements
in biotechnology, rising chronic disease prevalence, and a shift towards
personalized medicine. As the biopharmaceutical industry continues to evolve,
antibody fragments are expected to play an increasingly significant role in addressing
unmet medical needs. With ongoing research and development efforts, strategic
collaborations, and regulatory support, the market for antibody fragments is
likely to continue its upward trajectory in the coming years, ultimately
benefiting patients and healthcare providers worldwide.,” said Mr. Karan
Chechi, Research Director with TechSci Research, a research-based management
consulting firm.
“Antibody Fragments Market By Product
Type (FAB, scFv, sdAb, Others), By Application (Cancer, Immunodeficiency,
Others), By Specificity (Monoclonal Antibodies, Polyclonal Antibodies), By Region, By Competition Forecast &
Opportunities, 2018-2028F”, has evaluated the future growth potential of Global
Antibody Fragments Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Antibody
Fragments Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com